Online inquiry

IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15191MR)

This product GTTS-WQ15191MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15191MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7094MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ9343MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ11852MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ8985MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ3131MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ9323MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ5291MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ8152MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HL036337
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW